QRxPharma, an Australian company that has its U.S. headquarters in Bedminster, announced Wednesday that four board members, including the chairman, have resigned.
The resignations of Chairman Dr. Peter Farrell and director Dr. Gary Pace were effective Wednesday, ahead of the company’s general meeting, while those of directors Peter Campbell and Michael Quinn were effective Friday.
The resignations follow the U.S. Food and Drug Administration’s nonapproval letter for the company’s Moxduo new drug application on May 27.
"It has been an honor serving as QRxPharma chairman and I certainly share the frustration of shareholders with respect to the development of Moxduo and interactions with the FDA," Farrell said in a statement. "Speaking for the entire outgoing board, I am satisfied we are leaving the Company in a strong position to continue under the direction of the new board.”
ALSO ON NJBIZ:
Please note: All comments will be reviewed and may take up to 24 hours to appear on the site.View Comment Policy